SOURCES SOUGHT
A -- Reagent Resource Support Program for AIDS Vaccine Development
- Notice Date
- 12/18/2001
- Notice Type
- Sources Sought
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700-B Rockledge Drive, MSC 7612 Room 2230, Bethesda, MD, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- Reference-Number-SS-NIH-NIAID-DAIDS-03-01
- Response Due
- 1/10/2002
- Archive Date
- 1/25/2002
- Point of Contact
- Lois Eaton, Contract Specialist, Phone 301-496-0611, Fax 301-480-5253, - Barbara Shadrick, Senior Contracting Officer, Phone 301-496-7288, Fax 301-402-0972,
- E-Mail Address
-
le52u@nih.gov, bs92y@nih.gov
- Description
- THIS IS NOT AN RFP AND DOES NOT COMMIT THE NIH TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO RFP PACKAGE IS AVAILABLE AT THIS TIME. The Division of Acquired Immune Deficiency Syndrome (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) is recompeting a contract currently being performed by Quality Biological, Inc. (NIH Contract No. N01Al-65278). At this time, the NIH is soliciting tailored capability statements from qualified 8(a), HubZone and Small Business firms under the North American Industry Classification System (NAICS) Code 541710 with a size standard of 500 employees (SIC 8731). Based on the acceptable Capability Statements received from this SOURCES SOUGHT announcement, we reserve the right to solicit the proposed acquisition as an 8(a) Set-Aside, HubZone or Small Business Set-Aside. All 8(a), HubZone and Small Business contractors responding to this Sources Sought Announcement must have the capabilities to provide the following services: 1) produce (either through purchase or other means), purify, and test reagents for the DAIDS Vaccine and Prevention Research Program; these reagents include an array of viral proteins and peptides, virus stocks, monoclonal and polyclonal antibodies, topical microbicides, vaccine adjuvants and cytokines, and any additional reagents deemed necessary for the DAIDS vaccine program, 2) have capabilities for genetic cloning and sequencing, 3) be capable of producing (either through purchase or other means) and testing unique and customized reagents at the request of the program, including preparing and/or producing soluble proteins, expression vectors, and gene products (including experimental AIDS vaccines) under current Good Laboratory Practice (cGLP) or Good Manufacturing Practice (cGMP) as appropriate for their intended use, and preparing and/or producing these in large-scale production lots, 4) be able to analyze all acquired or generated reagents for purity and integrity, and to provide for their quality control and assurance, and 5) provide for appropriate receipt and inventory tracking, storage, maintenance and distribution of all reagents. The Contractor will be monitored by regular communications between the NIAID Project Officer and the contract Principal Investigator and through site visits by DAIDS staff. NIAID will receive written reports (quarterly updates and annual reports) as well as reports of data from individual studies in progress. All 8(a), HubZone or Small Business concerns that respond to this notice must furnish capability statements directed specifically to the requirements mentioned above. Sources possessing experience and demonstrated capability to accomplish the above are to supply pertinent information in sufficient detail to demonstrate the ability to perform the required services. Information furnished should include background information, resumes, a description of general and specific facilities, an outline of previous similar projects and other available literature for the NIH to perform a proper evaluation of the capability statement. See CBD Numbered Note 25. An original and one copy of the capability statement specific to this announcement must be submitted on the closing date identified above. Responses to the SOURCES SOUGHT may be submitted by Email to Lois Eaton at
- Place of Performance
- Address: The continental Unites States.
- Record
- SN20011220/00007289-011219090148 (fbodaily.com)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |